Dennis P. Calvert, President & CEO of BioLargo, Inc. Provides Key Updates and Outlook in a New Audio Interview with SmallCapVoice.com

Click here to listen to the interview!

AUSTIN, Texas, June 08, 2020 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (SCV) and BioLargo, Inc. (OTCQB:BLGO)(“the Company”), developer of sustainable technologies and a full-service environmental engineering company, today announced that a new audio interview with the Company is now available.

The interview featuring an overview of BLGO’s current news and moves can be heard at https://www.smallcapvoice.com/interview-biolargo-blgo/.

Dennis P. Calvert, President & CEO of BioLargo, discussed the Company’s business model and market segments with SmallCapVoice.com. With a wide array of issued patents, an extensive R&D talent pool, and a full-service engineering team, the company maintains a robust pipeline of products from inception through maturity.  BioLargo monetizes its technology assets with the goal of maximizing both impact and shareholder value, using licensing, strategic partnership, and direct-to-market strategies.

Recently, the Company’s patented CupriDyne® technology has been proven in a third-party study to be effective in inactivating SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic. In addition, BioLargo announced in May 2020 that Clyraguard, the product developed by its partially owned subsidiary Clyra Medical Technologies in response to the COVID-19 pandemic, has been successfully shown to cause complete inactivation of the SARS-CoV-2 virus in laboratory testing.

In the interview, Calvert commented, “As the [COVID-19] pandemic took hold, our teams had to ask themselves, ‘how do we make a difference’. At each level, our operating units took a deep dive looking at our portfolio of technologies and assets to come up with our unique responses. This has been the busiest, most intense, but also most unifying time for our team in the history of the Company. These are really exciting times for our company. We are thankful for the opportunity to share our story with our shareholders and the SmallCapVoice.com listening audience.

About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to "make life better". We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and licensor to our subsidiary Clyra Medical (www.clyramedical.com), which features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

About SmallCapVoice.com

SmallCapVoice.com, Inc. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies, small cap and micro-cap stocks build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, podcasts, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks in which they are interested. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTCMarkets. To learn more about SmallCapVoice.com and its services, please visit https://www.smallcapvoice.com/small-cap-stock-otc-investor-relations-financial-public-relations/.

Socialize with SmallCapVoice and their clients at;

Facebook: https://www.facebook.com/SmallCapVoice/  

Twitter: https://twitter.com/smallcapvoice   

Instagram: https://www.instagram.com/smallcapvoice/

Safe Harbor Act

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

For SmallCapVoice.com:

Stuart T. Smith

512-267-2430

ssmith@smallcapvoice.com

Source: SmallCapVoice.com

BioLargo Discusses Clyraguard, BioLargo PFAS Treatment Technology Scale-up and Commercialization, and Progress of South Korean Joint Venture with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - June 4, 2020) - The Stock Day Podcast welcomed BioLargo, Inc. (OTCQB: BLGO) ("the Company"), developer of sustainable technologies and a full-service environmental engineering company with a focus on clean water, clean air, and advanced antimicrobial products. President & CEO of BioLargo, Dennis P. Calvert, joined Stock Day host Everett Jolly for an interview.

Jolly began by asking about the Company's subsidiary, Clyra Medical Technologies Inc., which recently launched a new product called Clyraguard. "This is a personal protection spray," explained Calvert. "It is hospital-grade, FDA-registered and cleared, and is 99.99% effective. This is an absolute winner," said Calvert.

"How big do you think this product can become?", asked Jolly. Calvert shared that Clyraguard has the potential to benefit a wide variety of people. "We know that it is the perfect product for a frontline healthcare worker," said Calvert, adding that the product is also suitable for individuals that are considered high-risk or are simply looking for protection against a number of pathogens. "We don't know of any product that matches the feature benefits of this product," said Calvert.

Calvert shared that Clyra has already begun selling the product, which is currently retailing at around $25 for a four-ounce bottle. "[Clyra is] building distribution as we speak, and adding team members to really help build that distribution. So, we think this is going to be a big blockbuster for the company."

Jolly then asked about the Company's patented CupriDyne® Clean product, and about the progress of their joint venture in South Korea. Calvert shared that the Company has finalized a joint venture with one of the leading waste water treatment groups in South Korea. "We got that transaction put together just a few months ago," said Calvert, discussing the tremendous potential of this agreement as the effects of the pandemic begin to subside.

"Where are we at with the PFAS solution?", asked Jolly, commenting on the Company's industrial water treatment technology aimed at eliminating per- and polyfluoroalkyl substances (PFAS) from water, called the BioLargo AEC. Calvert explained that the BioLargo AEC is a solution to the PFAS crisis which is both effective and affordable. "We'd like to be in commercial trials within the next 120 days," he continued, adding that the primary focus of this project is currently to produce a scaled-up version of the technology, which company management expects will be completed soon. Calvert explained that potential commercial trial clients are lining up.

To close the interview, Calvert expressed the potential of the Company's long list of technologies, which have continued to advance despite the current challenges of the pandemic. "We think that the future is right here before us," closed Calvert.

To hear Dennis Calvert's entire interview, follow the link to the podcast here: https://audioboom.com/posts/7598978-biolargo-discusses-clyraguard-biolargo-pfas-treatment-technology-scale-up-and-commercialization

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/

About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to "make life better". We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and licensor to our subsidiary Clyra Medical (www.clyramedical.com), which features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact:

Name: Dennis P. Calvert
Phone: (888)-400-2863
Address: 14921 Chestnut St, Westminster CA, 92683
Email: dennis.calvert@biolargo.com

Safe Harbor Act

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.

SOURCE:

Stock Day Media

(602) 821-1102

BioLargo CEO Dennis Calvert Sits Down for Interview with TMA BlueTech about "Uncommon Paths to CEO"

BioLargo President & CEO Dennis P. Calvert sat down for an interview with Katarina Jones of TMA BlueTech to discuss "Uncommon Paths to CEO". He offers commentary for young entrepreneurs interested in leadership in technology and innovation.

TMA BlueTech is a leading innovation cluster focused on promoting development and dissemination of science and technology that can protect our water and oceans. BioLargo is proud to be a member of this terrific organization.

Dennis Calvert has been an entrepreneur from age 4!  Some of his thoughts about the keys to running a successful business include:
- Teamwork is critical
- You can’t do it alone, no matter how hard you try
- Find every person’s special gift
- Have passion for what you’re working on

Thanks to interviewer Katarina Jones!  Visit her podcast "Otherwise Insights" to see more of Katarina's work.

Johnny Sirpilla Joins BioLargo’s Subsidiary Clyra Medical Technologies as Chief Business Development Officer

Westminster, CA – June 2, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, today announced that experienced business executive John A. Sirpilla has expanded his role from the Advisory Board of BioLargo’s partially owned subsidiary Clyra Medical Technologies, Inc., to serve as Clyra’s Chief Business Development Officer.

In his new role at the company, Mr. Sirpilla will work with Clyra’s senior executive team on brand expansion and retail channel development, and will work to develop strategic partnerships to help make Clyra products widely available to individuals, businesses, and the healthcare industry.

Mr. Sirpilla is the former President of Camping World Accessory Stores, a 140-store nationwide retail chain serving the RV industry and was promoted in 2012 to Chief Business Development Officer for the parent company, Camping World and Good Sam with annual sales of nearly $4 billion.   He is currently the CEO and founder of Encourage LLC (www.encourage33.com), a family office focused on driving change in healthy living, leadership, and child adoption. A long-time resident of Canton Ohio, Mr. Sirpilla also sits on the board of trustees of the Pro Football Hall of Fame, Hall of Fame Health, publicly traded LCI, Aultman Health Foundation, and other medical device boards.
Mr. Sirpilla joins the Clyra team as the company launches its FDA registered Clyraguard Personal Protection Spray to help protect personal protective equipment from the SARS-CoV-2 Coronavirus (COVID-19).

Mr. Sirpilla commented, “At Camping World, a portion of my responsibilities involved the oversight of call center operations, buying & merchandising, parts and accessories inventory, distribution center supply chain, store operations, and wholesale distribution. I believe strongly that these experiences will help me propel Clyra to the success it deserves. Clyra’s products fit well in my philosophy that inspiring others can lead to a positive impact on the world.”

Clyraguard is a spray designed to help prevent cross contamination by the SARS-CoV-2 Coronavirus, the cause of COVID-19 disease of the personal protective equipment worn by both front-line healthcare workers and consumers. Registered with the FDA as a Class I general purpose disinfectant, Clyraguard features an extremely high antimicrobial efficacy at 99.999% kill rate (complete inactivation), and the recent testing showed it inactivates the COVID-19 coronavirus below the limits of detection of the testing model.

More information about Clyraguard can be seen at the Clyra Medical website:  www.clyramedical.com/clyraguard


About BioLargo, Inc.
BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and licensor to our subsidiary Clyra Medical (www.clyramedical.com), which features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

About Clyra Medical Technologies, Inc.
Clyra Medical Technologies (www.ClyraMedical.com) offers patented and patent pending effective, and safe, advanced antimicrobial products. Clyra has developed an FDA 510(k)-cleared product offering a Wound Irrigation Solution for advanced wound care available to hospitals and physicians in the U.S.

In addition, Clyra offers Clyraguard Personal Protective Spray, an effective, long-lasting disinfectant for personal protective equipment.

Clyra products are designed to offer the highest standards of antimicrobial and antiviral activity that are tissue and skin friendly, non-staining and are effective against biofilms.

Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.